DiaMedica Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
DiaMedica Therapeutics Inc. (DMAC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $918.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-23.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2020-03-23
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2019 was $918.00K, a 80.71% increase from fiscal 2018.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2018 was $508.00K, a 138.50% increase from fiscal 2017.
- DiaMedica Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2017 was $213.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2019-12-31 | $918.00K 10-K · filed 2020-03-23 |
| 2018-12-31 | $508.00K 10-K · filed 2020-03-23 |
| 2017-12-31 | $213.00K 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |